For Non-US Residents
Overall symptom improvement includes reductions
in “wearing-off” effect and symptom severity.
TASMAR® (tolcaphone) inhibits catechol-O-methyltransferase
(COMT), an enzyme that catalyzes the metabolization of levodopa into
This provides a prolonged maintenance of serum levodopa levels.
This means that TASMAR may give you or your loved one a longer clinical
response to levodopa treatments, which can help to control Parkinson’s
TASMAR® (tolcapone) improves Parkinson’s
disease symptom control by giving more ON time:
Increases ON time 1.7–2.9 hours and decreases OFF time 1.6–3.2
hours per 16-hour waking day.
71% (100 mg) to 91% (200 mg) improvement in investigators’ global
assessments of overall efficacy at 3 months.
• Improves motor function.
TASMAR SHOULD NOT BE USED BY PATIENTS UNTIL THERE
HAS BEEN A COMPLETE DISCUSSION OF THE RISKS AND THE PATIENT HAS PROVIDED
WRITTEN INFORMED CONSENT (SEE PATIENT ACKNOWLEDGEMENT FORM).
USE OF TASMAR REQUIRES WRITTEN
INFORMED CONSENT BY THE PATIENT (SEE
PATIENT CONSENT SECTION IN THE COMPLETE PRESCRIBING INFORMATION in the PI).
WARNING: Due to the risk of potentially fatal, acute fulminant liver failure,
TASMAR should ordinarily be used in patients with Parkinson’s disease on
levodopa/carbidopa who have symptom fluctuations and are not responding satisfactorily
to or who are not appropriate candidates for other adjunctive therapies (see
INDICATIONS and DOSAGE AND ADMINISTRATION in the PI).
TASMAR should not be initiated in patients with clinical evidence of liver disease
or 2 SGPT/ALT or SGOT/AST values greater than
the upper limit of normal (ULN) and should be discontinued if substantial clinical
benefit is not seen within 3 weeks. Patients with severe dyskinesia or dystonia
should be treated with caution (see
PRECAUTIONS: Rhabdomyolysis in the PI).
Frequent laboratory monitoring is essential (see
PRECAUTIONS:Laboratory Tests for the recommended schedule in the PI). Liver monitoring may not prevent
failure; however, early detection and immediate drug withdrawal are believed
to enhance the likelihood for recovery. Patients should be advised to self-monitor
for signs of liver disease. Discontinue TASMAR if hepatic enzymes exceed ULN
or patient exhibits signs of liver failure. Please see accompanying complete
prescribing information including BOXED WARNING.
TASMAR® is a registered trademark of Valeant Pharmaceuticals International